EP Lab Digest - March 2008 - (Page 26)

26 EP RESEARCH MARCH 2008 CLINICAL TRIALS Continued from page 25 study is powered as a non-inferiority trial to test the hypothesis that mortality in patients with no ICD is not more than 1% greater (absolute yearly increase) than patients receiving an ICD. Contact: Paul Dorian, MD and Marta Gadacz, MSc Title: The Role of MMP-9 and MMP-2 in Risk Stratification for VT/VF in Patients With Implanted Cardioverter Defibrillator Devices Number of Patients: 100 Trial Start Date: September 2006 Trial End Date: September 2008 Status: Recruiting Purpose: The primary objective of this cross-sectional study is to assess whether serum levels of MMP 2, 9, and evaluation of the genomic promoter sequence polymorphisms, correlate with episodes of VT/VF in patients who have implantable cardioverter defibrillator devices. Contact: Suzanne Adams, RN, MPH, Suzanne.Adams@jefferson.edu, Dr. Shaw Natan, MD, Shaw.Natan@mail.tju.edu Title: Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial Number of Patients: 100 Trial Start Date: January 2007 Trial End Date: November 2010 Status: Recruiting Purpose: The purpose of this randomized, double-blind research study is to evaluate the effectiveness of metoprolol, a beta blocker, in treating patients in the hospital with a cardiac arrest. Metoprolol will be given intravenously. The subjects who will take part in this study are 18 years of age or older, are experiencing a cardiac arrest in the hospital, and are in a life-threatening situation. Patients who develop a cardiac arrest require prompt electrical defibrillation to restore the normal beating rhythm of the heart. In patients who do not respond to electrical defibrillation, current standard of care recommends the use of medications that have been shown to be of unknown benefit. Some people recover from a cardiac arrest, but many do not. We want to learn whether giving metoprolol will improve survival of patients with a cardiac arrest. Patients will receive either the standard of care with the drug epinephrine or the standard of care plus metoprolol. Phase: II Contact: William Merhi, DO, Principal Investigator, William Beaumont Hospital, willmerhi@yahoo.com, David E. Haines, MD, Principal Investigator, dhaines@beaumont.edu Title: Effects of Endurance Training on Patients With Reduced LVEF and Cardiac Resynchronization Therapy Especially for Cardiac Arrhythmias Number of Patients: 30 Trial Start Date: August 2007 Trial End Date: December 2008 Status: Recruiting Purpose: A severely reduced left ventricular ejection fraction is associated with increased mortality due to pump failure as well as to malignant ventricular arrhythmia.We hypothesize that targeted training may lead to improved survival and to increased parameters of risk stratification for malignant arrhythmia. Additionally, the training may lead to an improved psychological and mental condition of the patients. Contact: Dirk Müller, MD, PhD, Principal Investigator, Charité, Campus Benjamin Franklin, d r. d i r k . mu e l l e r @ c h a r i t e. d e, Fernando C. Dimeo, MD, PhD, Principal Investigator, Charité, Campus Benjamin Franklin Title: Prospective, Multi-Center Study Of The Ability Of The PD2i Cardiac Analyzer To Predict Risk of VentrIcular TachyArrhythmic Events Such As Sudden Cardiac Death, VentricuLar Fibrillation or Ventricular Tachycardia in HighRisk Patients Number of Patients: 900 Trial Start Date: November 2006 Trial End Date: March 2009 Status: Recruiting Purpose: This is a prospective, longitudinal study evaluating the ability of the PD2i Cardiac Analyzer to predict the risk of serious heart rhythm abnormalities in high-risk patients that do not already have an ICD. Contact: David Fater, dfater@vicortech.com Supraventricular Tachycardia Title: Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia Number of Patients: 220 Trial Start Date: October 2006 Trial End Date: September 2010 Status: Recruiting Purpose: This is a randomized, doubleblind, multi-centered study to compare six months of medical treatment with digoxin or propranolol in infants with SVT. Neither digoxin nor propranolol has been evaluated for pediatric use in a controlled trial in the context of SVT, yet both medications are used frequently. The specific aims of the study are to determine whether propranolol and digoxin differ in the: 1) Incidence of recurrent SVT in infants after six months of treatment with propranolol or digoxin; 2) Time to first recurrence of SVT in infants treated with propranolol or digoxin; and 3) Incidence of adverse outcomes in infants treated with propranolol or

Table of Contents Feed for the Digital Edition of EP Lab Digest - March 2008

EP Lab Digest - March 2008 ECG 101: The Case of a Dizzy Patient with a Left Bundle Branch Block Delayed Defibrillation: Research and Results Interview with Paul S. Chan, MD Contents Letter from the Editor Spotlight Interview: St. Joseph’s Hospital Health Center Parent Heart Watch from 36,000 Feet… Perspectives from the Annual Leadership Conference Clinical Trial Overview: 2008 Are MRI-Safe Pacemakers and Leads on the Horizon? Q & A with J. Rod Gimbel, MD Navigating Tortuous Coronary Sinus Anatomy Using a Bipolar Lead Email Discussion Group: March 2008 Guidelines on ECG Interpretation Spotlight Interview Update: What Have We Learned? The Value of Educating Staff Events Calendar Industry News and Products Classifieds Advertisers Index In Memoriam

EP Lab Digest - March 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.